Financial Performance - Total revenues for Q3 2023 reached $216.033 million, a slight increase from $208.976 million in Q3 2022, while year-to-date revenues for 2023 were $599.214 million compared to $478.620 million in 2022, representing a 25.2% increase[15]. - Net income for Q3 2023 was $81.837 million, up from $61.634 million in Q3 2022, with year-to-date net income of $196.206 million compared to $144.427 million in 2022, reflecting a 36% increase[15]. - Operating income for Q3 2023 was $88.279 million, compared to $83.292 million in Q3 2022, with year-to-date operating income of $236.539 million versus $193.022 million in 2022[15]. - Total revenues for the three months ended September 30, 2023, were $216.0 million, compared to $209.0 million for the same period in 2022, representing a growth of 3.0%[110]. - Net income for the three months ended September 30, 2023, was $81.8 million, an increase from $66.8 million in the same period of 2022, reflecting a growth of 22.5%[110]. - Basic earnings per share for the third quarter of 2023 was $0.62, up from $0.45 in the same quarter of 2022, reflecting a 37.8% increase[172]. Cash and Assets - Cash and cash equivalents increased to $274.227 million as of September 30, 2023, compared to $234.195 million at the end of 2022, marking a 17% increase[13]. - Total assets grew to $1.892 billion as of September 30, 2023, up from $1.841 billion at the end of 2022, indicating a 2.8% increase[13]. - The company’s total stockholders' equity increased to $249.181 million as of September 30, 2023, from $169.798 million at the end of 2022, representing a 46.7% increase[13]. - As of September 30, 2023, total available-for-sale marketable securities amounted to $209.1 million, with gross unrealized losses of $0.2 million[112]. - The total estimated fair value of cash equivalents and available-for-sale marketable securities as of September 30, 2023, was $381.3 million, an increase from $320.3 million as of December 31, 2022, representing a growth of 19.1%[115]. Research and Development - Research and development expenses for Q3 2023 were $17.321 million, slightly higher than $16.705 million in Q3 2022, with year-to-date R&D expenses totaling $55.027 million compared to $44.041 million in 2022[15]. - Research and development expenses include salaries, benefits, and contract services, charged to operating expenses as incurred[97]. Collaborations and Licensing - The company has collaborations and licensing agreements with major pharmaceutical companies including Roche, Takeda, and Pfizer, which contribute to its revenue through royalties and milestone payments[29]. - The company has established ENHANZE collaboration agreements, granting partners worldwide licenses to develop products using its proprietary rHuPH20 enzyme[62]. - Revenue from collaborative agreements includes upfront payments and milestone payments, reported separately in the financial statements[93]. Product Sales and Royalties - Proprietary product sales include XYOSTED, TLANDO, and Hylenex recombinant, primarily sold to wholesale distributors and specialty pharmacies[82]. - Revenue from product sales is recognized upon delivery to wholesalers, reflecting variable considerations such as returns and discounts[83]. - Royalties for the three months ended September 30, 2023, were $114.4 million, compared to $99.6 million in 2022, reflecting a year-over-year increase of 14.5%[118]. - Product sales, net for the three months ended September 30, 2023, totaled $86.6 million, up from $61.4 million in the prior year, indicating an increase of 41.0%[118]. Debt and Financing - The company completed the sale of $720.0 million in aggregate principal amount of 1.00% Convertible Senior Notes due 2028, with net proceeds of approximately $702.0 million after fees[131]. - The company issued $805.0 million in aggregate principal amount of 0.25% Convertible Senior Notes due 2027, with net proceeds of approximately $784.9 million after fees[138]. - The total principal amount of convertible notes is $1,525 million, a slight decrease from $1,538.5 million as of December 31, 2022[153]. - The total interest expense for the nine months ended September 30, 2023, was $11,825 thousand, compared to $6,336 thousand for the same period in 2022, reflecting an increase of 87%[155]. Stock and Shareholder Returns - The company has a capital return program authorized to repurchase up to $750 million of outstanding stock over three years, with $200 million spent on repurchasing 4.5 million shares in 2022[167]. - As of September 30, 2023, the company has repurchased 12.6 million shares for $500.0 million at an average price of $39.81 per share, with $250.0 million remaining under the $750 million share repurchase plan[168]. - Share-based compensation expense for the three months ended September 30, 2023, totaled $9,367 thousand, up from $6,797 thousand in the same period of 2022, marking a 38% increase[163]. Future Outlook and Developments - Halozyme Therapeutics has not disclosed specific future guidance or new product developments in the provided financial statements[15]. - The company anticipates a potential launch of Tecentriq SC in the U.S. in 2024, following updates to manufacturing processes[183]. - In November 2023, the company entered a global collaboration with Acumen for the use of ENHANZE technology in a clinical stage monoclonal antibody candidate for Alzheimer's disease[183].

Financial Performance - Total revenues for the second quarter of 2023 reached $221.038 million, a 45.0% increase compared to $152.365 million in the same period of 2022[15] - Net income for the second quarter of 2023 was $74.754 million, significantly up from $22.685 million in the same quarter of 2022, representing a 229.5% increase[15] - Earnings per share (EPS) for the second quarter of 2023 were $0.57 (basic) and $0.56 (diluted), compared to $0.16 (basic) and $0.16 (diluted) in the same quarter of 2022[15] - Operating income for the first half of 2023 was $148.260 million, up from $109.730 million in the first half of 2022, marking a 35.0% increase[15] - The company reported a net income of $114,369 million for the six months ended June 30, 2023, compared to a net income of $22,685 million for the same period in 2022[23] - For the three months ended June 30, 2023, total revenues were $221.0 million, compared to $163.4 million for the same period in 2022, representing a 35.3% increase[108] - The net income for the six months ended June 30, 2023, was $114.4 million, up from $96.8 million in the same period of 2022, reflecting an 18.2% increase[108] Cash and Assets - Cash and cash equivalents at the end of June 2023 were $221.165 million, down from $234.195 million at the end of December 2022[13] - Total current assets increased to $765.745 million as of June 30, 2023, compared to $739.013 million at the end of 2022[13] - The company reported a significant increase in accounts receivable, net and contract assets, which rose to $246.179 million from $231.072 million year-over-year[13] - As of June 30, 2023, total stockholders' equity was $151,033 million, an increase from $140,448 million as of March 31, 2023, reflecting a net income of $74,754 million for the quarter[23] - As of June 30, 2023, total assets amounted to $251.8 million, a decrease of 21.4% from $320.3 million on December 31, 2022[113] Liabilities and Equity - Total liabilities decreased slightly to $1.659 billion as of June 30, 2023, from $1.672 billion at the end of 2022[13] - The company reported depreciation and amortization expense of approximately $5.4 million for the six months ended June 30, 2023, compared to $1.9 million for the same period in 2022[122] - Accrued expenses totaled $136.3 million as of June 30, 2023, compared to $126.9 million as of December 31, 2022, an increase of 7.0%[123] Research and Development - Research and development expenses for the second quarter of 2023 were $19.727 million, compared to $15.483 million in the same quarter of 2022, reflecting a 27.5% increase[15] - Research and development expenses include salaries, benefits, and contract services, charged to operating expenses as incurred[95] Revenue Recognition - Revenue is generated from royalties at an average mid-single digit percent rate from ENHANZE technology collaborations, with noncancelable amounts owed once the triggering event occurs[57] - The company recognizes revenue based on estimates of royalties earned, with adjustments recorded in the following quarter if necessary[57] - Revenue from licenses is recognized at the point when the license becomes effective, typically at the inception of the agreement[63] - The company recognizes revenue from bulk rHuPH20 sales upon transfer of title to partners, who then bear the risk of loss and have an enforceable obligation to pay[88] - Revenue from collaborative agreements includes upfront payments and sales milestones, reported separately in the income statements[91] Collaborations and Partnerships - The company has collaborations with major pharmaceutical companies, including Roche, Takeda, and Pfizer, which generate royalties from commercial sales of approved partner products[27] - Halozyme's proprietary enzyme, rHuPH20, facilitates subcutaneous delivery of drugs, potentially improving patient experience and outcomes[26] - The company has commercialized auto-injector products and has development programs with several pharmaceutical companies, enhancing its product portfolio[28] - The company anticipates continued growth through its innovative drug delivery technologies and collaborations with biopharmaceutical partners[26] Stock and Shareholder Activities - The company has a capital return program authorized to repurchase up to $750 million of outstanding stock over three years, with $200 million spent in 2022 to repurchase 4.5 million shares[164] - As of June 30, 2023, Halozyme repurchased a total of 12.6 million shares for $500 million at an average price of $39.81 per share under a $750 million share repurchase plan[180] - The company issued 240,223 shares of common stock in connection with stock option exercises during the six months ended June 30, 2023, generating net proceeds of approximately $4.2 million[163] Debt and Financing - The company completed the sale of $720.0 million in aggregate principal amount of 1.00% Convertible Senior Notes due 2028, with net proceeds of approximately $702.0 million after fees[130] - The company issued $805.0 million in aggregate principal amount of 0.25% Convertible Senior Notes due 2027, with net proceeds of approximately $784.9 million after fees[137] - The company completed the sale of $460.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due 2024, with net proceeds of approximately $447.3 million after fees[142] - As of June 30, 2023, the total principal amount of convertible notes is $1,525 million, a slight decrease from $1,538.483 million as of December 31, 2022[150] Product Development and Approvals - The company is actively developing auto-injector products and has commercialized products like Hylenex and XYOSTED utilizing its technology[178] - NOCDURNA is the first and only sublingual tablet indicated for nocturia treatment, reducing nighttime urination by nearly 50%[187] - TLANDO was granted FDA approval in March 2022 and launched commercially in June 2022[188] - Roche's collaboration includes the development of multiple products using ENHANZE technology, with significant launches such as Herceptin SC and Phesgo[192][193] - Takeda's HYQVIA received FDA approval for adult primary immunodeficiency treatment, with a dosing regimen requiring only one infusion up to once per month[196] Market and Competitive Position - Halozyme's ENHANZE technology is designed to reduce patient treatment burden by enabling fixed-dose subcutaneous dosing compared to weight-based intravenous dosing[26] - Hylenex recombinant is currently the number one prescribed branded hyaluronidase[185] - XYOSTED is the only FDA-approved subcutaneous testosterone enanthate product for once-weekly self-administration[186]

NASDAQ: HALO May 2023 Forward Looking Statements Non-GAAP Financial Measures: Note: This presentation contains product names, trademarks and registered trademarks that are property of their respective owners. | --- | --- | --- | |-------------------------------------------------------------------------|--------------------------------------------------------|-------------------------------------------| | ENHANZE ® | Drug Delivery Platform Technologies \nAuto-Injectors | Commercial Portfolio \nSpecialty Prod ...

Financial Data and Key Metrics Changes - The company reported total revenue of $162 million for Q1 2023, a 38% increase year-over-year from $117.3 million in Q1 2022 [10][17] - Royalty revenue for the quarter was $99.6 million, representing a 43% increase compared to $69.6 million in the prior year period [32][126] - EBITDA for the quarter was $74.3 million, compared to $76.4 million in Q1 2022, reflecting a $25 million milestone payment in the previous year that did not recur [20][19] - GAAP diluted earnings per share was $0.29, while non-GAAP diluted earnings per share was $0.47 [20] Business Line Data and Key Metrics Changes - The ENHANZE royalty business is experiencing strong growth, with expectations to add three new agreements in 2023 [3][6] - XYOSTED revenue is projected to reach approximately $100 million in 2023, representing a 20% increase from the run rate following the acquisition [7] - The company anticipates continued strength in ENHANZE wave 2 products, with royalty revenue expected to increase between 23% to 26% over 2022 [21][126] Market Data and Key Metrics Changes - Roche reported Q1 2023 revenues of CHF1.6 billion for OCREVUS, a 14% year-over-year increase, with annualized sales exceeding $7 billion [12] - The subcutaneous formulation of DARZALEX has achieved an 88% market share in the US and over 80% outside the US, driving significant revenue growth [128] - Phesgo sales reached approximately CHF240 million in Q1 2023, a 72% year-over-year increase, with 85% of patients preferring subcutaneous administration [129] Company Strategy and Development Direction - The company aims to expand its product pipeline and advance products through development to regulatory approval, targeting multiple new royalty revenue streams [13][136] - There is a strong focus on enhancing the competitiveness of products through subcutaneous delivery, which is expected to reduce treatment times and improve patient experience [102][124] - The company is actively evaluating M&A opportunities to enhance revenue growth and durability [116] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving goals for 2023, including new ENHANZE deals and continued growth in royalty revenue [6][11] - The company anticipates reaching approximately $1 billion in royalty revenue by 2027, with potential for growth beyond that [104] - Management noted that current partners are awaiting more details from CMS regarding IRA guidance, which has not significantly impacted discussions [24][120] Other Important Information - The company completed $150 million in share repurchases in Q1 2023, fully utilizing the allocated amount for the year [16][90] - Research and development expenses increased to $18 million in Q1 2023, primarily due to a larger workforce and planned investments in ENHANZE [19] Q&A Session Summary Question: How is the IRA guidance impacting conversations with potential partners? - Management indicated that there is still too little detail available to assess any impact, and IRA has not been a frequent topic in discussions with potential partners [24][120] Question: What is the expected impact of the Antares acquisition on earnings? - The Antares acquisition is expected to be accretive to revenue and non-GAAP EPS for the full year 2023 [90] Question: Can you provide more details on planned investments in ENHANZE? - Planned investments focus on developing a high-yield rHuPH20 and a room temperature stable version, which may be suitable for small molecules [88][89] Question: What is the current IV to subcutaneous conversion rate trajectory for other products? - The company expects a target conversion rate of around 60% after three years, with positive progress noted for products like Phesgo [80][95]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 ___________________________ HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ___________ ...

• 13-20% YoY growth • Excludes impact of future share repurchases | --- | --- | --- | --- | --- | |---------------|---------|-----------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | Total Revenue | $660.1M | $815M ...

NASDAQ: HALO February 21, 2023 In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's financial outlook for 2023) and expectations for profitability, revenue (including expectations for future royalties, milestones and product sales), EBITDA and earnings-per-share, and the Company's plans to repurchase shares under ...

PART I [Business](index=8&type=section&id=Item%201.%20Business) Halozyme Therapeutics licenses its ENHANZE® drug delivery technology and expanded its portfolio with the 2022 Antares Pharma acquisition, focusing on a capital-light model - The company's core business is licensing its ENHANZE® drug delivery technology, which uses the rHuPH20 enzyme to convert intravenous (IV) drugs to subcutaneous (SC) injections, to major biopharmaceutical companies[27](index=27&type=chunk) - In 2022, Halozyme acquired Antares Pharma, Inc., adding advanced auto-injector technologies and a portfolio of commercial products (XYOSTED®, TLANDO®, NOCDURNA®) to its business[28](index=28&type=chunk)[380](index=380&type=chunk) - The company operates a capital-light model by outsourcing all manufacturing of its rHuPH20 enzyme and device components to third-party contract manufacturing organizations like Avid Bioservices, Catalent, and Phillips-Medisize[90](index=90&type=chunk)[91](index=91&type=chunk)[94](index=94&type=chunk) - As of February 14, 2023, the company had **393 full-time employees**, with a workforce composition of **45% female** and **31% non-white/Caucasian**[105](index=105&type=chunk)[109](index=109&type=chunk) [Risk Factors](index=28&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks from partner dependence, technology concentration, debt, and Antares acquisition integration challenges - A primary risk is the heavy reliance on partners (e.g., Roche, Janssen) to successfully develop and commercialize products using ENHANZE® technology; failure or termination of these collaborations would significantly harm the business[130](index=130&type=chunk) - The business is highly concentrated on the rHuPH20 enzyme; any adverse development, such as safety issues or manufacturing disruptions with contract manufacturers (Avid, Catalent), could impact the entire ENHANZE® platform and Hylenex®[127](index=127&type=chunk)[131](index=131&type=chunk) - The company has significant debt, totaling approximately **$1.5 billion** as of December 31, 2022; this includes multiple series of convertible notes and covenants under a credit agreement, which could restrict operations and require substantial cash for debt service[149](index=149&type=chunk)[150](index=150&type=chunk) - Failure to successfully integrate the Antares business, or underperformance of its products and technologies, could adversely impact future business, operations, and the ability to realize anticipated revenue diversification and growth[141](index=141&type=chunk)[142](index=142&type=chunk) [Unresolved Staff Comments](index=45&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) The company reports no unresolved staff comments from the Securities and Exchange Commission - There are no unresolved staff comments[210](index=210&type=chunk) [Properties](index=46&type=section&id=Item%202.%20Properties) Halozyme operates from approximately 194,000 square feet of leased facilities across San Diego, Ewing, and Minnetonka - The company leases all its facilities, totaling approximately **194,000 square feet** as of December 31, 2022[211](index=211&type=chunk) - Key locations include administrative and research facilities in San Diego, CA, an office in Ewing, NJ, and a multi-purpose facility (office, lab, manufacturing, warehouse) in Minnetonka, MN[211](index=211&type=chunk) [Legal Proceedings](index=46&type=section&id=Item%203.%20Legal%20Proceedings) Halozyme is not currently involved in any legal proceedings expected to materially impact its financial position - As of the report date, Halozyme is not a party to any legal proceedings expected to have a material adverse effect on the company[212](index=212&type=chunk) [Mine Safety Disclosures](index=46&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[213](index=213&type=chunk) PART II [Market For Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=47&type=section&id=Item%205.%20Market%20For%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) Halozyme's common stock trades on NASDAQ, with a focus on share repurchases rather than dividends, and strong stock performance - The company's common stock is listed on the NASDAQ Global Select Market under the symbol **"HALO"**[216](index=216&type=chunk) - Halozyme has never paid dividends and does not intend to in the foreseeable future, prioritizing reinvestment and share repurchases[217](index=217&type=chunk) - In December 2021, the Board authorized a new three-year, **$750 million** share repurchase program; as of December 31, 2022, the company had repurchased **8.4 million shares** for **$350.0 million** under this program[219](index=219&type=chunk) Q3 2022 Share Repurchase Details | Period | Total Number of Shares Purchased | Weighted Average Price paid Per Share | Total Cost (in thousands) | | :--- | :--- | :--- | :--- | | Q3 2022 | 4,500,216 | $44.44 | $200,000 | [(Reserved)](index=50&type=section&id=Item%206.%20%28Reserved%29) This item is reserved [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=51&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Halozyme's 2022 revenues grew significantly due to royalties and Antares acquisition, though operating income slightly decreased due to increased expenses [Results of Operations](index=55&type=section&id=7.1%20Results%20of%20Operations) Halozyme's 2022 financial performance saw strong royalty and product sales growth, but increased operating expenses and a one-time tax benefit reversal impacted net income Financial Performance Summary | Financial Metric (in thousands) | 2022 | 2021 | % Change | | :--- | :--- | :--- | :--- | | **Total Revenues** | **$660,116** | **$443,310** | **48.9%** | | Royalties | $360,475 | $203,900 | 76.8% | | Product sales, net | $191,030 | $104,224 | 83.3% | | Revenues under collaborative agreements | $108,611 | $135,186 | (19.7)% | | **Total operating expenses** | **$392,585** | **$167,408** | **134.5%** | | Cost of sales | $139,304 | $81,413 | 71.1% | | Amortization of intangibles | $43,148 | $0 | N/A | | Research and development | $66,607 | $35,672 | 86.7% | | Selling, general and administrative | $143,526 | $50,323 | 185.2% | | **Operating income** | **$267,531** | **$275,902** | **(3.0)%** | | **Net income** | **$202,129** | **$402,710** | **(49.8)%** | - The significant decrease in net income from **$402.7 million** in 2021 to **$202.1 million** in 2022 was primarily due to a one-time income tax benefit of **$154.2 million** in 2021 from the release of a valuation allowance, compared to an income tax expense of **$46.8 million** in 2022[245](index=245&type=chunk)[365](index=365&type=chunk) [Liquidity and Capital Resources](index=56&type=section&id=7.2%20Liquidity%20and%20Capital%20Resources) Halozyme maintains strong liquidity with $362.8 million in cash, managing cash flows from operations, investing, and financing activities - The company held **$362.8 million** in cash, cash equivalents, and marketable securities as of December 31, 2022[247](index=247&type=chunk) Cash Flow Activities | Cash Flow Activity (in millions) | 2022 | 2021 | | :--- | :--- | :--- | | Net cash provided by operating activities | $240.1 | $299.4 | | Net cash used in investing activities | ($487.0) | ($406.3) | | Net cash provided by financing activities | $362.4 | $77.9 | - Material future cash requirements include long-term debt service, lease payments (**$47.0 million**), third-party manufacturing obligations (**$97.8 million**), and other purchase commitments (**$48.7 million**)[249](index=249&type=chunk)[250](index=250&type=chunk)[251](index=251&type=chunk)[252](index=252&type=chunk) [Long-Term Debt](index=58&type=section&id=7.3%20Long-Term%20Debt) Halozyme's long-term debt primarily consists of convertible senior notes, with recent issuance of 2028 notes and repayment of other facilities Convertible Notes Summary | Convertible Note Series | Principal Amount (in millions) | Interest Rate | Maturity Date | | :--- | :--- | :--- | :--- | | 2028 Notes | $720.0 | 1.00% | Aug 15, 2028 | | 2027 Notes | $805.0 | 0.25% | Mar 1, 2027 | | 2024 Notes | $13.5 | 1.25% | Dec 1, 2024 | - In August 2022, the company issued **$720.0 million** of **1.00% Convertible Senior Notes due 2028** and entered into Capped Call Transactions for **$69.1 million** to reduce potential dilution upon conversion[258](index=258&type=chunk)[516](index=516&type=chunk) - The company completed induced conversions of its 2024 notes, paying down **$77.4 million** in principal in August 2022 and **$369.1 million** in March 2021[270](index=270&type=chunk)[271](index=271&type=chunk) - In August 2022, the company repaid its entire outstanding term loan facility and all outstanding loans under its revolving credit facility; the revolving credit facility was increased to **$575 million** and was undrawn as of December 31, 2022[276](index=276&type=chunk)[277](index=277&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=64&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is interest rate fluctuations on its investment portfolio, which management deems immaterial - The primary market risk is interest rate fluctuations affecting the value of the company's cash equivalents and marketable securities portfolio[284](index=284&type=chunk) - Management estimates that a hypothetical **10% change** in interest rates would not have a material impact on the company's financial results[284](index=284&type=chunk) - The company does not hold or issue derivative instruments for speculative or trading purposes[285](index=285&type=chunk) [Financial Statements and Supplementary Data](index=64&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section presents the company's audited consolidated financial statements and the independent auditor's report for 2022 - This section includes the audited consolidated financial statements and the report from the independent registered public accounting firm, Ernst & Young LLP[286](index=286&type=chunk)[299](index=299&type=chunk) [Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](index=64&type=section&id=Item%209.%20Changes%20in%20and%20Disagreements%20with%20Accountants%20on%20Accounting%20and%20Financial%20Disclosure) The company reports no changes in or disagreements with its accountants regarding accounting principles or financial disclosure - None reported[287](index=287&type=chunk) [Controls and Procedures](index=65&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management and auditors concluded that disclosure controls and internal control over financial reporting were effective, excluding the recently acquired Antares Pharma - Management concluded that both disclosure controls and procedures and internal control over financial reporting were effective as of December 31, 2022[290](index=290&type=chunk)[296](index=296&type=chunk) - The assessment of internal control over financial reporting explicitly excluded the operations of Antares Pharma, Inc., acquired in May 2022; Antares constituted **9% of total assets** and **17% of total revenues** for the year[291](index=291&type=chunk)[295](index=295&type=chunk)[302](index=302&type=chunk) - The independent auditor, Ernst & Young LLP, provided an unqualified opinion on the effectiveness of the company's internal control over financial reporting as of December 31, 2022[301](index=301&type=chunk) [Other Information](index=68&type=section&id=Item%209B.%20Other%20Information) The company reports no other information under this item - None[309](index=309&type=chunk) [Disclosure Regarding Foreign Jurisdictions that Prevent Inspections](index=68&type=section&id=Item%209C.%20Disclosure%20Regarding%20Foreign%20Jurisdictions%20that%20Prevent%20Inspections) The company reports no information under this item, indicating it is not applicable - None[310](index=310&type=chunk) PART III [Directors, Executive Officers and Corporate Governance](index=68&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) This section provides executive officer biographies and incorporates director and governance information by reference from the 2023 Proxy Statement - Dr. Helen I. Torley has served as President and CEO since January 2014, bringing experience from leadership roles at Onyx, Amgen, and Bristol-Myers Squibb[312](index=312&type=chunk) - Nicole LaBrosse was appointed SVP, Chief Financial Officer in February 2022, having been with the company since 2015 and previously working as an auditor at PricewaterhouseCoopers, LLP[313](index=313&type=chunk) - Information concerning directors, the code of conduct, and board committees is incorporated by reference from the forthcoming 2023 Annual Meeting Proxy Statement[311](index=311&type=chunk) [Executive Compensation](index=69&type=section&id=Item%2011.%20Executive%20Compensation) All executive compensation information is incorporated by reference from the company's 2023 definitive Proxy Statement - All information regarding executive compensation is incorporated by reference from the 2023 Proxy Statement[318](index=318&type=chunk) [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=69&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) This section details the company's equity compensation plans, including shares available for future issuance, and incorporates other ownership data by reference Equity Compensation Plan Information | Plan Category | Shares to be Issued (a) | Weighted-Average Exercise Price of Options (b) | Shares Available for Future Issuance (c) | | :--- | :--- | :--- | :--- | | Equity compensation plans approved by stockholders | 6,550,450 | $24.99 | 17,413,834 | - The shares available for future issuance include **2,650,103 shares** available under the Employee Stock Purchase Plan (ESPP)[320](index=320&type=chunk) [Certain Relationships and Related Transactions, and Director Independence](index=70&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) Information on related party transactions and director independence is incorporated by reference from the company's 2023 definitive Proxy Statement - All information regarding certain relationships, related transactions, and director independence is incorporated by reference from the 2023 Proxy Statement[323](index=323&type=chunk) [Principal Accounting Fees and Services](index=70&type=section&id=Item%2014.%20Principal%20Accounting%20Fees%20and%20Services) Details on fees paid to the independent accounting firm are incorporated by reference from the company's 2023 definitive Proxy Statement - All information regarding principal accounting fees and services is incorporated by reference from the 2023 Proxy Statement[324](index=324&type=chunk) PART IV [Exhibits, Financial Statement Schedules](index=70&type=section&id=Item%2015.%20Exhibits%2C%20Financial%20Statement%20Schedules) This section lists all financial statements, schedules, and exhibits included in the Annual Report on Form 10-K - This section provides an index of all financial statements, schedules, and exhibits filed with the 10-K report[326](index=326&type=chunk)[327](index=327&type=chunk)[329](index=329&type=chunk) [Form 10-K Summary](index=73&type=section&id=Item%2016.%20Form%2010-K%20Summary) No summary is provided under this item - None[335](index=335&type=chunk)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communication Helen Torley - President & Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Michael DiFiore - Evercore ISI Jessica Fye - JPMorgan David Risinger - SVB Securities Jason Butler - JMP Corinne Jenkins - Goldman Sachs Operator Good afternoon. My name is Shantou, and I will b ...

Halozyme Confidential and Proprietary Third Quarter 2022 Financial and Operating Results Nasdaq: HALO November 8, 2022 Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's financial outlook for 2022) and expectations for profitability, revenue (including expectations for future milestone ...